Ben Fidler
Senior Editor | @BentheFidlerBen is a senior editor for BioPharma Dive. He is a veteran business journalist with 15 years of experience covering a variety of sectors. Prior to joining Industry Dive, Ben spent six-plus years with Xconomy writing about biotech, specializing in unique angles, profiles, features, enterprise pieces and more. A lifelong New Yorker, Brooklyn transplant and Yankees/Giants/Knicks fan, Ben is trying to cope with a recent move to the suburbs of Virginia, where he spends most of his time chasing after his rambunctious toddler. Ben has a B.A. from Binghamton University.
334 articles by Ben Fidler
-
US turns to Gilead's COVID-19 drug to help counter omicron
Jan. 24, 2022 -
Alnylam, awaiting key study data, builds case for its next rare disease drug
Jan. 21, 2022 -
UCB to buy Zogenix for nearly $2B in 'first step' for M&A in 2022
Jan. 19, 2022 -
Roche revives a closely watched Huntington's disease drug
Jan. 18, 2022 -
JPM22: Aftershocks for Lilly, CRISPR versus CRISPR and Bluebird's crucial year
Jan. 12, 2022 -
JPM22: M&A anxiety, Roche's comeback plan and Vir's omicron moment
Jan. 11, 2022 -
Sarepta, with new Duchenne results, to broach 'possibility' of speedy gene therapy approval
Jan. 10, 2022 -
Allogene cleared by FDA to resume 'off the shelf' cancer cell therapy trials
Jan. 10, 2022 -
As three biotechs head to Wall Street, a battered sector braces for a pullback
Jan. 7, 2022 -
Sanofi cuts ties with Sangamo, sharpening focus on 'off-the-shelf' cell therapy
Jan. 6, 2022 -
5 FDA approval decisions to watch in the first quarter
Jan. 5, 2022 -
10 clinical trials to watch in the first half of 2022
Jan. 3, 2022 -
US pauses distribution of Regeneron, Lilly antibodies over omicron concerns
Dec. 23, 2021 -
Sanofi, GSK say COVID vaccine works as booster, but delay key study results
Dec. 15, 2021 -
In final analysis, Pfizer's COVID-19 pill remains highly effective
Dec. 14, 2021 -
Bristol Myers returns to Immatics for a dual-targeting cancer drug
Dec. 14, 2021 -
Arena, completing its turnaround, sells to Pfizer for nearly $7 billion
Dec. 13, 2021 -
Latest Roche results show promise for new type of cancer immunotherapy
Dec. 10, 2021 -
Intercept, awaiting needed trial data, pulls its NASH drug application in Europe
Dec. 9, 2021 -
Omicron cuts Pfizer vaccine's potency, but data show booster may restore protection
Dec. 8, 2021 -
AstraZeneca wagers $200M on Ionis' next chance at a rare disease drug
Dec. 7, 2021 -
Regeneron warns its antibody drug may be less potent versus omicron
Nov. 30, 2021 -
Heart attacks struck Sek Kathiresan's family. He's devoted his life to stopping them.
Nov. 29, 2021 -
New Merck study results raise questions about its COVID pill
Nov. 26, 2021 -
Pfizer, BioNTech to seek full approval as COVID-19 vaccine efficacy holds up in young teens
Nov. 22, 2021